Aptorum Group Ltd Logo

Aptorum Group Ltd

Clinical-stage biopharma developing therapeutics for oncology and infectious diseases.

APM | US

Overview

Corporate Details

ISIN(s):
KYG6096M1069
LEI:
Country:
United States of America
Address:
17 HANOVER SQUARE, LONDON

Description

Aptorum Group Ltd. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to address unmet medical needs. The company's research and development pipeline targets a range of therapeutic areas, including orphan oncology, infectious diseases, and metabolic diseases. Key projects include SACT-1, a repurposed drug candidate for neuroblastoma, and ALS-4, an anti-virulence, non-bactericidal therapeutic for infections caused by Staphylococcus aureus. Additionally, the company is developing its RPIDD (Rapid Pathogen Identification and Detection Diagnostics) platform, a liquid biopsy-based technology for rapidly identifying and detecting pathogens.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-09-02 13:08
Half yearly financial reports and audit reports/limited reviews / Half yearly f…
English 268.2 KB
2020-09-01 08:00
Information and report on corporate governance
English 2.4 MB
2020-09-01 08:00
Half yearly financial reports and audit reports/limited reviews / Terms of avai…
English 17.0 KB
2020-09-01 08:00
Inside Information / Other news releases
English 54.9 KB
2020-09-01 08:00
Inside Information / Other news releases
English 35.4 KB
2020-08-28 15:17
Inside Information / Other news releases
English 526.2 KB
2020-08-27 16:27
Information and report on corporate governance
English 624.5 KB
2020-08-26 08:00
Inside Information / Other news releases
English 7.5 KB
2020-08-20 08:00
Inside Information / Other news releases
English 7.1 KB

Automate Your Workflow. Get a real-time feed of all Aptorum Group Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aptorum Group Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aptorum Group Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.